Multicenter evaluation of the Abbott IMx ® CA 15-3 ™ assay

Clinical Chemistry

Volumn 42, Issue 1, 1996, Pages 28-33

  Van Kamp, Gerard J ^a   Bon, Gijsbert G ^a   Verstraeten, Rob A ^a   Lynch, Don ^b   Krikau, Mark ^b   Flückiger, Jürg ^c   Ruibal, Alvaro ^d   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ABBOTT LABORATORIES   (United States)

^c Labor Dr B Güntert   (Switzerland)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Adenocarcinomas; Microparticle enzyme immunoassay; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; AUTOANALYZER; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; REPRODUCIBILITY;

ANIMALS; AUTOMATION; CA-15-3 ANTIGEN; EVALUATION STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; NEOPLASMS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 0030045555     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.1.28     Document Type: Article

References (17)

1. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumour-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
2. Hilkens J, Ligtenberg MJL, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biol Sci 1992;17:359-63.
3. Bon GG, Kenemans P, van Kamp GJ, Yedema CA, Hilgers J. Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. Nucl Med Allied Sci 1990;34(Suppl 3):151-62.
4. Tobias R, Rothwell C, Wagner J, Green A, Liu Y-SV. Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 [Abstract]. Clin Chem 1985;31:986.
5. Bon GG, Kenemans P, Yedema CA, van Kamp GJ, Nijman HW, Hilgers J. Clinical relevance of the tumor marker CA 15-3 in the management of cancer patients. In: Crommelin DJA, Schellekens H. eds. From clone to clinic. Amsterdam: Kluwer Academic Publishers. 1990:111-22.
6. Yedema CA, Kenemans P, Wobbes T, Thomas CMG, Bon GG, Mulder C, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumor Biol 1991;13:18-26.
7. Kenemans P, Bast R, Yedema C, Price M, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 1988;11/12:119-44.
8. Ruibal A, Encabo G, Genolla J, Guarga A, Urriuta A, Colomer R. Serum CA 15-3 levels in patients with general pathology and malignant diseases (excluding breast cancer). Bull Cancer (Paris) 1986;73:94-5.
9. Hilkens J, Buys F, Hilgers J, Hageman P, Calafat J, Sonnenberg A, van der Valk M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206.
10. Hilkens J, Kroezen V, Bonfrer JMG, de Jong-Bakker M, Bruning PF. MAM-6, a new serum marker for breast cancer monitoring. Cancer Res 1986;46:2582-7.
11. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3:223-32.
12. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
13. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. CNn Chem 1993;39:561-77.
14. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11/12:55-101.
15. Klapdor R. Arbeitsgruppe Qualitätskontrolle und Standardisierung von Tumormarkertests im Rahmen der Hamburger Symposien über Tumormarker. Tumordiagn Ther 1992;13:XIX.
16. Bon GG, Kenemans P, Verstraeten R, van Kamp GJ. Serum tumor marker immunoassays in gynecological oncology: establishment of reference values. Am J Obstet Gynecol 1996;(in press).
17. Jaeger W, Kramer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest 1995;55(Suppl 221):87-92.